Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients

Table 1 Characteristics of the HBV carriers receiving chemotherapy for non-Hodgkin’s lymphoma

	HBV reactivation (-)			HBV reactivation (+)
	Total	n	%	n	%	P
Number of patients	49	18	36.7	31	63.3
Median follow-up (yr)	6.2	5.4		6.7
Age (yr)
≤45	24	13	54.2	11	45.8	0.019
>45	25	5	20	20	80
Sex
Female	21	7	33.3	14	66.7	0.7689
Male	28	11	39.3	17	60.1
HBeAg
Positive	7	5	71.4	2	28.6	0.0841
Negative	42	13	31	29	69
Pre-chemotherapy HBV DNA
≥100 copy numbers	11	8	72.7	3	27.3	0.010
<100 copy numbers	38	10	26.3	28	73.7
HBV genotype C
Yes	12	5	41.7	7	58.3	0.7318
No	32	11	34.4	21	65.6
Unknown or mixed type	5	2	40	3	60
Tumor overall response (complete remission and partial remission)
Yes	26	8	30.8	18	69.2	0.3897
No	23	10	43.5	13	56.5